About Oyster Point Pharmaceuticals
Oyster Point Pharmaceuticals is a company based in Princeton (United States) founded in 2015 was acquired by Viatris in November 2022.. Oyster Point Pharmaceuticals has raised $121.61 million across 2 funding rounds from investors including Viatris, Invus and Flying L Partners. The company has 303 employees as of December 31, 2021. Oyster Point Pharmaceuticals offers products and services including EFFEXOR and Generics. Oyster Point Pharmaceuticals operates in a competitive market with competitors including Remegen, Biophytis, Azura Ophthalmics, TearSolutions and Retrotope, among others.
- Headquarter Princeton, United States
- Employees 303 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Oyster Point Pharma, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Oyster Point Pharmaceuticals
Oyster Point Pharmaceuticals offers a comprehensive portfolio of products and services, including EFFEXOR and Generics. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Medication for treating generalized anxiety disorder.
Affordable alternatives to branded drugs for various conditions.
Unlock access to complete
Unlock access to complete
Funding Insights of Oyster Point Pharmaceuticals
Oyster Point Pharmaceuticals has successfully raised a total of $121.61M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $93 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $93.0M
-
First Round
First Round
(24 Oct 2017)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2019 | Amount | Series B - Oyster Point Pharmaceuticals | Valuation | Invus , Flying L Partners | |
| Oct, 2017 | Amount | Series A - Oyster Point Pharmaceuticals | Valuation | New Enterprise Associates , Versant Ventures |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Oyster Point Pharmaceuticals
Oyster Point Pharmaceuticals has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include Viatris, Invus and Flying L Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Long-term private equity investments in transformational opportunities are pursued.
|
Founded Year | Domain | Location | |
|
Flying L Partners is focused on ophthalmic sector investments.
|
Founded Year | Domain | Location | |
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Oyster Point Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Oyster Point Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Oyster Point Pharmaceuticals Comparisons
Competitors of Oyster Point Pharmaceuticals
Oyster Point Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Remegen, Biophytis, Azura Ophthalmics, TearSolutions and Retrotope, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for cancer, autoimmune, and eye diseases are developed.
|
|
| domain | founded_year | HQ Location |
Drugs for neuromuscular and age-related diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developing therapies for meibomian gland dysfunction
|
|
| domain | founded_year | HQ Location |
Topical therapeutics for the treatment of dry eye disease
|
|
| domain | founded_year | HQ Location |
Therapeutics for neurodegenerative and ophthalmological diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Oyster Point Pharmaceuticals
Frequently Asked Questions about Oyster Point Pharmaceuticals
When was Oyster Point Pharmaceuticals founded?
Oyster Point Pharmaceuticals was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Where is Oyster Point Pharmaceuticals located?
Oyster Point Pharmaceuticals is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.
Who is the current CEO of Oyster Point Pharmaceuticals?
Jeffrey Nau is the current CEO of Oyster Point Pharmaceuticals.
Is Oyster Point Pharmaceuticals a funded company?
Oyster Point Pharmaceuticals is a funded company, having raised a total of $121.61M across 2 funding rounds to date. The company's 1st funding round was a Series A of $28.61M, raised on Oct 24, 2017.
How many employees does Oyster Point Pharmaceuticals have?
As of Dec 31, 2021, the latest employee count at Oyster Point Pharmaceuticals is 303.
What is the annual revenue of Oyster Point Pharmaceuticals?
Annual revenue of Oyster Point Pharmaceuticals is $24.54M as on Dec 31, 2021.
What does Oyster Point Pharmaceuticals do?
Founded in 2015 and headquartered in Princeton, United States, the company focuses on biotechnology within the ophthalmology sector. Gene therapies targeting ocular surface diseases are developed using an adeno-associated virus-based approach known as Enriched Tear Film therapy. The pipeline encompasses OC-01, a nasal spray for dry-eye disease; OC-103, intended for severe allergic conjunctivitis; and OC-101, aimed at neurotrophic keratopathy. Operations center on advancing these therapies through clinical development.
Who are the top competitors of Oyster Point Pharmaceuticals?
Oyster Point Pharmaceuticals's top competitors include Remegen, Lineage Cell Therapeutics and TearSolutions.
What products or services does Oyster Point Pharmaceuticals offer?
Oyster Point Pharmaceuticals offers EFFEXOR and Generics.
Who are Oyster Point Pharmaceuticals's investors?
Oyster Point Pharmaceuticals has 6 investors. Key investors include Viatris, Invus, Flying L Partners, NEA, and Versant Ventures.